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Colorectal cancer is an important public health problem. Several screening methods have been shown to be
effective in reducing colorectal cancer mortality. The objective of this review was to assess the cost-effectiveness of
the different colorectal cancer screening methods and to determine the preferred method from a cost-effectiveness
point of view. Five databases (MEDLINE, EMBASE, the Cost-Effectiveness Analysis Registry, the British National
HealthServiceEconomicEvaluation Database,andthelistsoftechnologyassessmentsoftheCentersforMedicare
and Medicaid Services) were searched for cost-effectiveness analyses published in English between January
1993 and December 2009. Fifty-ﬁve publications relating to 32 unique cost-effectiveness models were identiﬁed.
All studies found that colorectal cancer screening was cost-effective or even cost-saving compared with no screen-
ing. However, the studies disagreed as to which screening method was most effective or had the best incremental
cost-effectiveness ratio for a given willingness to pay per life-year gained. There was agreement among studies that
the newly developed screening tests of stool DNA testing, computed tomographic colonography, and capsule
endoscopy were not yet cost-effective compared with the established screening options.
colonography, computed tomographic; colonoscopy; colorectal neoplasms; cost-beneﬁt analysis; mass screening;
occult blood; sigmoidoscopy
Abbreviations: CTC, computed tomographic colonography; FIT, fecal immunochemical test; FOBT, fecal occult blood test; LYG,
life-year gained; USPSTF, U.S. Preventive Services Task Force.
INTRODUCTION
More than 1 millionpeopleworldwide are newly diagnosed
with colorectal cancer each year (1). Approximately half of
these patients die of the disease, making colorectal cancer the
fourth leading cause of cancer death in the world (1). Screen-
ing can prevent many of these deaths by detecting colorectal
cancer in an early, more treatable stage and by detecting and
removing its nonmalignant precursor lesion, the adenoma,
thereby preventing colorectal cancer incidence (2, 3). Colo-
rectal cancer screening is not only an effective tool for re-
ducing colorectal cancer mortality but also has been estimated
to do so at acceptable costs. In 2002, Pignone et al. (4) con-
ducted a systematic review for the U.S. Preventive Services
Task Force (USPSTF) showing that, compared with those for
no colorectal cancer screening, the costs per life-year gained
(LYG) of several colorectal cancer screening strategies were
all less than $50,000 per LYG. However, when the established
colorectal cancer screening strategies were compared, no
strategy was consistently found to be the most effective or
to be the preferred strategy for a given willingness to pay (4).
The uncertainty about what is the most (cost-)effective
test has resulted in a wide variety of screening strategies
being offered worldwide. Guidelines in the United States
recommend that individuals undergo screening with one
of several options (5, 6), whereas the European Union rec-
ommends screening with only a guaiac fecal occult blood
test (FOBT) (7). Initiatives to implement nationwide colo-
rectal cancer screening programs are currently being de-
veloped in Canada (8) and several European countries (9).
Given the large budget deﬁcits most countries currently
face, it is of great importance that resources be used efﬁ-
ciently and that a cost-effective option for colorectal cancer
screening be chosen.
Options for colorectal cancer screening are evolving rap-
idly. Several screening methods that were either not under
consideration or unavailable at the time of the USPSTF
review have since been deemed viable options (5). Included
are computed tomographic colonography (CTC) and stool
DNA testing, as well as the screening option currently rec-
ommended in several countries—fecal immunochemical
88 Epidemiol Rev 2011;33:88–100testing (FIT) (10–13). Therefore, this paper aims to provide
an updated review of the cost-effectiveness of colorectal
cancer screening to inform policy makers and others who
may be deciding which colorectal cancer screening strategy
to recommend or implement. Speciﬁcally, we examined the
following 3 questions:
1. How do the costs and LYGs from colorectal cancer
screening with the established screening tests (i.e.,
guaiac FOBT, sigmoidoscopy, the combination of sig-
moidoscopy and guaiac FOBT, and colonoscopy) com-
pare with those for no screening?
2. Do the results of the cost-effectiveness analyses of the
established screening options point to an optimal strategy
for screening?
3. Are the newly developed screening tests FIT, stool DNA
testing, CTC, and capsule endoscopy cost-effective com-
pared withthe established colorectal cancer screening tests?
MATERIALS AND METHODS
We conducted this review according to the framework for
reviews of economicanalyses(14).We searchedMEDLINE,
EMBASE, the Cost-Effectiveness Analysis Registry (https://
research.tufts-nemc.org/cear/default.aspx), the British
National Health Service Economic Evaluation Database
(http://www.crd.york.ac.uk/CMS2Web/AboutNHSEED.asp;
http://www.crd.york.ac.uk/CMS2Web/SearchPage.asp), and
the lists of technology assessments of the Centers for
Medicare and Medicaid Services (http://www.cms.gov/
medicare-coverage-database/indexes/technology-assessments-
index.aspx?bc¼BAAAAAAAAAAA&) for cost-effectiveness
analyses published between January 1993 (the year the ﬁrst
trial of colorectal cancer screening was published) and
December 2009. We used different queries matching the
keywords in each database to identify the relevant cost-
effectiveness analyses. Web Appendix 1 contains an over-
view of the search queries. (This Appendix and all other
supplementary Web material mentioned in this review are
posted on the Epidemiologic Reviews Web site (http://epirev.
oxfordjournals.org/).)To identify studies notcaptured by our
database searches, we manually checked the reference lists
of retrieved articles.
We used similar criteria for exclusion and inclusion of
articles, as in the USPSTF review (4), excluding studies that
werenotcost-effectivenessorcost-utilityanalyses;studiesfor
whichcostsper(quality-adjusted)LYGcouldnotbecorrectly
calculated;studiesthatdidnotcontainoriginalanalyses;stud-
ies that did not address at least one of our research questions;
and studies performed from perspectives other than the soci-
etal perspective or payer perspective. We did include studies
using non-US cost or disease estimates. When multiple pub-
lications were retrieved from the same cost-effectiveness
model, we included the most comprehensive analysis and
used the other papers for supplemental information.
For each included study, we extracted the life-years
and costs per person for each strategy evaluated. When nec-
essary, costs were translated to US dollars by using the
exchange rate reported in the studies. If not reported, we
usedhistoricexchange rates fromJuly1 (oran adjacent date,
if rates for July 1 were unavailable) of the year in which cost
estimates were expressed (15). Costs were updated to 2010
US dollars by using the Consumer Price Index for medical
care (16).Ifno baseyearforthecostestimateswasexplicitly
mentioned in a study, we assumed that costs were expressed
in the currency of the year 2 years prior to publication.
To answer the second and third research questions (i.e.,
about the cost-effectiveness of screening tests), we per-
formed an incremental cost-effectiveness analysis. Speciﬁ-
cally, we ranked the strategies in order of increasing
effectiveness. If one strategy was more costly and less ef-
fective than another strategy, it was considered to be
strongly dominated. If a strategy was both less effective
and provided additional years of life at a higher cost than
a more effective strategy (i.e., it had a higher incremental
cost-effectiveness ratio), it was considered to be weakly
dominated. Incremental cost-effectiveness ratios were then
recalculated for each nondominated strategy by dividing the
additional cost of a speciﬁc strategy by its additional clinical
beneﬁt compared with the next less expensive strategy. The
calculated incremental cost-effectiveness ratios will almost
always differ from the incremental cost-effectiveness ratios
reported in the studies because of the cost adjustments,
and because some studies reported cost per LYG with each
strategy compared with no screening.
RESULTS
Identiﬁcation of cost-effectiveness analyses
The search (conducted in January 2010) retrieved a total
of 641 citations. Of these, 217 were duplicates and were
excluded, leaving 424 citations for further consideration. In
total, 297 relevant abstracts were reviewed in detail, with 123
articles retrieved forpossible inclusion in the review. Fifty-six
publications relating to 32 unique colorectal cancer models
were considered in this review. Web Figure 1 shows the rea-
sons for excluding the remaining articles. Through a manual
search of the reference lists of retrieved articles, we identiﬁed
2 additional studies that met our inclusion criteria (17, 18).
Both concerned additional analyses with models already
included in this review. This review includes 5 new studies
with US-based costs and disease incidence not yet included
in the USPSTF review (19–22) and 2 studies with updated
estimates from previously included models (22, 23).
Study descriptions
Web Table 1 presents the characteristics of all 32 studies
included in this review. Thirty studies reported costs per
LYG from colorectal cancer screening, 2 reported costs
per quality-adjusted LYG only (24, 25), and 2 reported costs
per LYG and either costs per quality-adjusted LYG (26) or
costs per disability-adjusted LYG (27). Seven studies were
published in 1993–1999 (18, 25, 28–32), 13 in 2000–2004
(20, 24, 27, 33–42), and 12 in 2005–2009 (19, 21–23,
26, 43–47). Fourteen analyses evaluated colorectal cancer
screening in North America (13 in the US population
and one in the Canadian population). Ten studies were
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Australia. The majority of studies used a third-party payer
perspective, and approximately half evaluated lifetime costs
and beneﬁts; the remainder evaluated time horizons from 10
to 50 years. Three percent and 5% were the most commonly
used discount rates. Only 3 United Kingdom studies used
a different discountrate(25,26,45).Adherenceassumptions
ranged from 40% to 100%, with adherence between 60%
and 70% and 100% adherence most often used. Only 2
studies considered differential adherence between screening
tests.
The studies differed widely in the screening strategies
evaluated. US and Asian studies generally assessed many
colorectal cancer screening strategies and typically evalu-
ated annual FOBT as opposed to biennial FOBT. European
and Australian studies more often included biennial FOBT.
The strategies that have long been recommended in US
guidelines, namely, annual and biennial unrehydrated
guaiac FOBT, 5-yearly sigmoidoscopy, the combination
of 5-yearly sigmoidoscopy and annual guaiac FOBT, and
10-yearly colonoscopy, were evaluated most frequently,
each in at least 9 studies. Because it is impossible to exam-
ine all analyzed colorectal cancer screening strategies in
this review, we focused on these established colorectal can-
cer screening strategies when addressing the ﬁrst 2 research
questions. For guaiac FOBT, we focused on Hemoccult II
(Beckman Coulter, Inc., Brea, California) because this test
was evaluated in large randomized trials and has therefore
been evaluated most in the cost-effectiveness studies. If
a study did not explicitly mention the guaiac FOBT under
consideration, we assumed it was Hemoccult II.
Web Table 2 gives a more detailed overview of assump-
tions for the 12 models that evaluated at least the strategies
of annual guaiac FOBT, 5-yearly sigmoidoscopy, and 10-
yearly colonoscopy. Nine of 12 models explicitly simulate
the natural history of colorectal cancer, but only 4 allow for
multiple adenomas within one individual and explicitly sim-
ulate different parts of the gastrointestinal tract. Eight
models assume that all colorectal cancers arise from adeno-
mas, whereas 2 assume that 15%–30% of colorectal cancers
arise without a precursor lesion.
The models differ most strongly on the dwell time, with
estimates ranging from 5 to 87 years. These dwell times
reﬂect the average time it would take an adenoma to
become cancer in the absence of death. In reality, the
faster-growing adenomas are mainly the ones that become
cancer in a person’s lifetime, so the average time a diag-
nosed cancer has been present is shorter than this average,
particularly in the models with long adenoma dwell times.
Many of the included studies acknowledge that dwell
time is the most uncertain parameter in their model.
The difference in dwell time seems to arise from the
modeling philosophy followed when estimating adenoma
dwell time. Short adenoma dwell times were from models
that directly input a dwell time (distribution) based on
assumption or expert opinion, whereas the longer ade-
noma dwell times resulted from models that did not di-
rectly input dwell time but rather simulated probabilities
of transitioning through a series of health states. The
values of these transition probabilities were obtained by
calibrating the models to data on adenoma prevalence in
autopsy studies and polyp growth rates in observational
studies.
With respect to test characteristics, the models are in
agreement regarding endoscopy sensitivity. However, sensi-
tivity of guaiac FOBT for cancer varies from 25% to 60%
between the models. These estimates all pertain to the
Hemoccult II test, but differences in rehydration of the test
between the models may explain some of the difference
in assumed characteristics. Whether guaiac FOBT screening
was based on unrehydrated or rehydrated analysis was often
not reported in the studies.
As a result of the described differences in model as-
sumptions, the colorectal cancer mortality reduction is also
strikingly different from model to model. The mortality re-
duction from annual guaiac FOBT varies from 18% to 80%,
that from 5-yearly sigmoidoscopy from 23% to 68%, that
from 10-yearly colonoscopy from 39% to 90%, and that
from the combination of annual guaiac FOBT and 5-yearly
sigmoidoscopy from 71% to 88%. There is even greater
variety in test costs between the models. Translated to
2009 US dollars, guaiac FOBT costs $1 in one model com-
pared with $59 in another, sigmoidoscopy $43 compared
with $622, and colonoscopy $80 compared with $1,570.
Even when looking at US-based studies only, test costs
still vary from $5 to $59 for guaiac FOBT, $149 to $622
for sigmoidoscopy, and $533 to $1,570 for colonoscopy.
Although we adjusted for the year of the study by updating
all cost estimates to 2009 dollars, doing so does not fully
account for differences by year (or for differences by set-
ting) because nominal Medicare reimbursement rates for
screening procedures have not increased over time while
costs in other settings have.
Question 1: Costs and LYGs of established screening
strategies compared with no screening
The estimated effectiveness of screening, measured in
discounted LYGs compared with no screening, differed con-
siderably between the studies (Table 1). For example, the
LYGs with annual FOBTranged from 0.006 in the study that
found the smallest effectiveness to 0.160 in the study that
found the greatest effectiveness, an almost 30-fold differ-
ence. Part of this difference can be explained by differences
in study design: the ﬁrst study looked at costs and effects on
the level of a population cohort (including individuals from
0 to 100 years of age), whereas the latter study looked at
a cohort of only those aged 50 years. Because costs and
effects of screening are accumulated mostly in the popula-
tion aged 50–75 years, dividing the costs over a total pop-
ulation cohort results in signiﬁcantly lower per-person costs
and effects than when dividing over the number of persons
aged 50 years only. However, differences in study design
were insufﬁcient to explain most of the differences in costs
and effectiveness between studies. For example, 2 studies
evaluated annual FOBT screening in a US cohort of persons
aged 50 years followed for life, assuming 100% adherence
with screening (37, 41). The LYGs with this strategy varied
from 0.019 to 0.100 across models, a more than 5-fold
difference.
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Study: First Author,
Year (Reference No.)
a
Annual gFOBT Biennial gFOBT Flexible Sigmoidoscopy
Every 5 Years
Flexible Sigmoidoscopy
Every 5 Years 1 Annual
gFOBT
Colonoscopy Every 10 Years
LYG Cost Cost/LYG LYG Cost Cost/LYG LYG Cost Cost/LYG LYG Cost Cost/LYG LYG Cost Cost/LYG
Flanagan, 2003 (34) 0.025 328 13,100 0.016 185 11,600
Frazier, 2000 (35) 0.042 825 19,600 0.039 751 19,500 0.059 1,523 26,000 0.048 1,514 31,700
Gyrd-Hansen, 1998 (28) 0.006 36 6,400 0.004 20 5,300
Hassan, 2007 (44) 0.036  10 CS
Helm, 2000 (36) 0.014 72 4,000
Khandker, 2000 (37) 0.100 2,519 25,600 0.090 1,904 22,500 0.110 3,553 32,400 0.110 3,487 31,500
Lejeune, 2004 (38) 0.029 126 4,400
Leshno, 2003 (39) 0.160  158 CS 0.182  324 CS 0.180  26 CS
Macafee, 2008 (45) 0.009 30 3,400
O’Leary, 2004 (40) 0.021 2,883 9,800
Pickhardt, 2007 (19) 0.046 495 10,700
Shimbo, 1994 (32) 0.013 750 56,300
Song, 2004 (20) 0.056 508 9,100 0.048 940 19,600 0.063 1,347 21,500 0.062 1,330 21,500
Sonnenberg, 2000 (41) 0.019 285 15,100 0.036 2,059 56,600 0.080 1,355 17,000
Steele, 2004 (42) 0.008 94 11,700 0.012 132 11,400 0.019 515 26,800
Stone, 2004 (27) 0.001 23 15,500
Tappenden, 2007 (26) 0.026 147 5,700
Tsoi, 2008 (46) 0.094 651 7,000 0.110 989 9,000 0.159 1,281 8,100
Vijan, 2007 (23) 0.029 202 6,800 0.031 948 30,100 0.050 1,138 22,800 0.053 544 10,200
Wagner, 1995 (18) 0.059 1,086 18,500 0.036 705 19,700 0.067 1,461 21,700 0.059 1,028 17,300
Whynes, 1998 (25) 0.017 76 4,600
Wu, 2006 (47) 0.025  27 CS 0.014 35 2,500 0.025  2C S
Zauber (MISCAN), 2009 (22) 0.066  88 CS 0.077 102 1,300 0.085 133 1,600 0.087 205 2,400
Zauber (SimCRC), 2009 (22) 0.060  305 CS 0.069  231 CS 0.087  315 CS 0.094  207 CS
Zauber (CRC-SPIN), 2009 (22) 0.064  471 CS 0.080  375 CS 0.095  413 CS 0.106  403 CS
Abbreviations: Cost, net costs (in US dollars) of the screening strategy compared with no screening; CS, cost-saving; gFOBT, guaiac fecal occult blood test with Hemoccult II (Beckman
Coulter, Inc., Brea, California); LYG, life-year gained compared with no screening.
a The paper by Zauber et al. (22) contained analyses from 3 independently developed colorectal cancer models: MISCAN, SimCRC, and CRC-SPIN.
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0Web Table 2 indicates several reasons for this difference.
First, the sensitivity of guaiac FOBTwas assumed to be 40%
in the Sonnenberg et al. study (with 0.019 LYG) compared
with 60% in the Khandker et al. study (with 0.100 LYG),
a 1.5-fold difference. Furthermore, Khandker et al. assume
an additional 10% sensitivity for adenomas with each test
use; in the Sonnenberg et al. study, no sensitivity for ade-
nomas is reported. Witha 10%sensitivityforadenomaseach
year, an adenoma has a more than 65% probability of being
detected after 10 consecutive guaiac FOBTs, assuming
conditional independence of repeat testing(which allmodels
seem to assume). This additional 65% probability of de-
tection of an adenoma can be expected to give substantial
extra LYGs with screening compared with no extra beneﬁt
from adenoma detection in the Sonnenberg et al. model.
Despite these differences, all studies consistently found
that colorectal cancer screening was cost-effective com-
pared with no screening for each of the established screen-
ing strategies (Table 1): for all models, the costs per LYG
of the established screening strategies were less than
$60,000, and only 2 were more than $50,000. Six models
found one or more colorectal cancer screening strategies
to be cost-saving. Biennial guaiac FOBTwas the only strat-
egy not found to be cost-saving. However, none of the
models that found one or more screening strategies to be
cost-saving evaluated biennial guaiac FOBT. If they had,
biennial guaiac FOBT would have likely been found cost-
saving as well. The costs per LYG of each screening strat-
egy differed widely between the studies. Compared with
those for no screening, costs per LYG for annual guaiac
FOBT varied from cost-saving to more than $56,000, for
biennial guaiac FOBT from $3,400 to $16,000, for 5-yearly
sigmoidoscopy from cost-saving to $57,000, for the com-
bination of 5-yearly sigmoidoscopy and annual guaiac
FOBT from cost-saving to $26,000, and for colonoscopy
from cost-saving to $34,000.
No distinctive pattern was found between the cost-
effectiveness ratios in US studies compared with non-US
studies. The range of cost-effectiveness ratios from US
studies was so wide that it included the ranges reported
in studies outside the United States. For example, the cost
per LYG of annual FOBT compared with no screening
ranged in US studies from cost-saving to almost $26,000,
whereas the same ratio in the European studies ranged from
$6,400 to almost $12,000.
Although the previous review for the USPSTF already
concluded that colorectal cancer screening was highly
cost-effective (4), the cost-effectiveness of colorectal cancer
screening seems to have further improved over time. The
cost-effectiveness ratios in the US studies published after
the review for USPSTF (19, 20, 22, 23) were generally
lower (i.e., more favorable) compared with those reported
in the review (18, 35, 37, 41, 48). For example, the cost per
LYG of colonoscopy screening compared with no screening
ranged from $13,000 to $32,000 in the older studies versus
cost-saving to $19,000 in the newer studies. Similar ﬁndings
were observed for the other strategies. One study explicitly
reappraised the cost-effectiveness of colorectal cancer
screening over time in light of the rising colorectal cancer
treatment costs (49). This study showed that the costs per
LYG of colorectal cancer screening had indeed decreased
over time as a result of an increase in treatment costs; guaiac
FOBT and FIT changed from being highly cost-effective
compared with no screening in the past to being cost-saving
in the present.
Question 2: Do cost-effectiveness analyses point to an
optimal strategy for screening?
Eight models evaluated all 4 screening strategies that
have been recommended in the United States since 1997:
annual guaiac FOBT, 5-yearly sigmoidoscopy, a combina-
tion of 5-yearly sigmoidoscopy and annual guaiac FOBT,
and 10-yearly colonoscopy (Table 2). The models differed
with respect to which strategy was most effective in terms
of discounted LYGs: 5 found 10-yearly colonoscopy to
be most effective (22, 23, 37) and 3 the combination of
sigmoidoscopy and FOBT (18, 20, 35).
When the 3 models that found the combination strategy
most effective are compared with the 5 that found colonos-
copy most effective, an important difference in assumptions
for adenoma sensitivity of guaiac FOBT is evident (Web
Table 2). Theformerstudiesallassumeasensitivityforsmall
adenomas of 8%–10%, whereas the latter studies assume
sensitivities for small adenomas of 2%–6%. Although this
differenceinsensitivitymayseem minor,a 5%sensitivity for
small adenomas leads to less than 40% of adenomas being
detected after 10 consecutive FOBTs compared with more
than 65% with 10% sensitivity (again assuming conditional
independence of repeat testing). Of the studies that found
colonoscopy to be the most effective test, the Khandker
et al. study (Web Table 2) had the highest sensitivity for
small adenomas with guaiac FOBT (6%). In this study, the
LYGs with the combination of ﬂexible sigmoidoscopy and
guaiac FOBT are almost identical to those for colonoscopy,
supporting our argument that the sensitivity of guaiac
FOBT for adenomas is an important determinant of the
relative effectiveness of colonoscopy versus the combi-
nation of ﬂexible sigmoidoscopy and guaiac FOBT.
At the commonly used willingness-to-pay threshold of
$50,000 per LYG, colonoscopy was the preferred method
of screening in 4 of the 8 analyses, the combination strategy
of annual guaiac FOBTand sigmoidoscopy in 2, and annual
FOBT and sigmoidoscopy alone in 1 each. Besides the dif-
ferences in effectiveness between the tests described before,
the test costs are important drivers of these differences in
optimal strategies. For example, endoscopy costs in the
study by Song et al. (Web Table 2) are considerably higher
compared with the costs of FOBT, whereas the additional
beneﬁt of endoscopy over FOBT is negative (sigmoidos-
copy) to small (10% additional mortality reduction for
colonoscopy), explaining why FOBT was found to be the
optimal strategy. In the Khandker et al. study, we observe
the opposite, with sigmoidoscopy costs being quite low
compared with those of FOBT or colonoscopy, explaining
why that strategy is the optimal one.
An additional 5 studies also evaluated all these strategies
with the exception of the combination of sigmoidoscopy
and FOBT (Table 3). When only the remaining 3 strate-
gies of annual guaiac FOBT, 5-yearly sigmoidoscopy, and
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found colonoscopy to be the most effective. Furthermore,
8 of the 12 studies found colonoscopy to be the preferred
method if $50,000 per LYG was willing to be paid. FOBT
and sigmoidoscopy were found to be the preferred strategy
in 2 studies each.
Question 3: Cost-effectiveness of newly developed
screening tests compared with established tests
Since the review for the USPSTF was published in
2002 (4), FIT, stool DNA testing, and CTC have been
deemed acceptable options for colorectal cancer screening,
at least by some societies (5). Capsule endoscopy is not
mentioned in any of the average-risk colorectal cancer
screening guidelines.
Seven studies have evaluated FIT screening (Table 4) (22,
32, 33, 43, 49). Three evaluated a hypothetical ‘‘average’’
FIT, whereas the remaining studies all evaluated a different
FIT. Sensitivity for cancer and speciﬁcity were comparable
between studies. Four studies found FIT to be cost-saving
compared with no screening, and all showed acceptable
costs per LYG compared with no screening. Approximately
half of the studies found FIT to be a dominant screening
strategy, providing more life-years for lower costs than the
comparator strategies. The other half found that FIT was
Table 3. Preferred Strategy From Incremental Cost-effectiveness Analysis (US Dollars) at Different Thresholds of
Willingness-to-Pay for a Life-year Gained for the 7 Models That Evaluated Annual Fecal Occult Blood Testing, 5-Yearly
Sigmoidoscopy, and 10-Yearly Colonoscopy
Study: First Author,
Year (Reference No.)
a
Willingness-to-Pay for a LYG
$10,000/LYG $20,000/LYG $50,000/LYG $100,000/LYG
Frazier, 2000 (35) No screening FSIG gFOBT gFOBT
Khandker, 2000 (37) No screening No screening FSIG COL
Song, 2004 (20) gFOBT gFOBT gFOBT gFOBT
Sonnenberg, 2000 (41) No screening COL COL COL
Steele, 2004 (42) No screening FSIG FSIG COL
Tsoi, 2008 (46) COL COL COL COL
Vijan, 2007 (23) gFOBT COL COL COL
Wagner, 1995 (18) No screening COL COL COL
Wu, 2006 (47) gFOBT gFOBT COL COL
Zauber (MISCAN), 2009 (22) gFOBT COL COL COL
Zauber (SimCRC), 2009 (22) COL COL COL COL
Zauber (CRC-SPIN), 2009 (22) COL COL COL COL
Abbreviations: COL, 10-yearly colonoscopy; FSIG, 5-yearly ﬂexible sigmoidoscopy; gFOBT, annual guaiac fecal occult
blood test with Hemoccult II (Beckman Coulter, Inc., Brea, California); LYG, life-year gained.
a The paper by Zauber et al. (22) contained analyses from 3 independently developed colorectal cancer models: MISCAN,
SimCRC, and CRC-SPIN.
Table 2. Preferred Strategy From Incremental Cost-effectiveness Analysis (US Dollars) at Different Thresholds of Willingness-
to-Pay for a Life-year Gained for the 7 Models That Evaluated the 4 US Colorectal Cancer Screening Strategies Recommended
Since 1997
Study: First Author,
Year (Reference No.)
a
Willingness-to-Pay for a LYG
$10,000/LYG $20,000/LYG $50,000/LYG $100,000/LYG
Frazier, 2000 (35) No screening FSIG FSIG þ gFOBT FSIG þ gFOBT
Khandker, 2000 (37) No screening No screening FSIG COL
Song, 2004 (20) gFOBT gFOBT gFOBT gFOBT
Vijan, 2007 (23) gFOBT COL COL COL
Wagner, 1995 (18) No screening COL COL FSIG þ gFOBT
Zauber (MISCAN), 2009 (22) gFOBT FSIG þ gFOBT FSIG þ gFOBT COL
Zauber (SimCRC), 2009 (22) COL COL COL COL
Zauber (CRC-SPIN), 2009 (22) COL COL COL COL
Abbreviations: COL, 10-yearly colonoscopy; FSIG, 5-yearly ﬂexible sigmoidoscopy; gFOBT, annual guaiac fecal occult blood test
with Hemoccult II (Beckman Coulter, Inc., Brea, California); LYG, life-year gained.
a The paper by Zauber et al. (22) contained analyses from 3 independently developed colorectal cancer models: MISCAN,
SimCRC, and CRC-SPIN.
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Am J Epidemiol 2011;33:88–100Table 4. (Incremental) Cost-effectiveness of Newly Developed Colorectal Cancer Screening Strategies Compared With no Screening and With Established Tests
Strategy and Study: First Author,
Year (Reference No.)
a Study Details Comparator Strategies CER
b ICER
b,c
FIT Test Used
d Sensitivity for
Cancer, Speciﬁcity Test Costs
b
Berchi, 2004 (33) Magstream 82, 96 12 gFOBT 3,900
Chen, 2007 (43) OC-SENSOR 64.6–84.6, 77.1–97.1 3 No screening CS Dominant
Parekh, 2008 (49) Insure FIT 76, 91 25 gFOBT, COL,
stool DNA test
CS Dominant
Shimbo, 1994 (32) Reversed passive
hemagglutination
assay
48.1–84.3, 99 13 gFOBT 25,900 Dominant
Zauber, 2009 (MISCAN) (22) Mix of tests 70, 95 24 gFOBT, SENSA,
COL, FSIG,
CTC, FSIG þ gFOBT
800 Dominated by SENSA
Zauber, 2009 (SimCRC) (22) Mix of tests 70, 95 24 gFOBT, SENSA,
COL, FSIG,
CTC, FSIG þ gFOBT
CS Dominated by SENSA
Zauber, 2009 (CRC-SPIN) (22) Mix of tests 70, 95 24 gFOBT, SENSA,
COL, FSIG,
CTC, FSIG þ gFOBT
CS Dominated by SENSA
Stool DNA Test Used
d Sensitivity for
Cancer, Speciﬁcity Test Costs
b
Leshno, 2003 (39) PreGen-Plus 91, 90 86 gFOBT, COL,
FSIG þ gFOBT
600 Dominated by COL and
FSIG þ gFOBT
Parekh, 2008 (49) PreGen-Plus 65, 95 879 gFOBT, COL, FIT 17,500–23,700 Dominated by all tests
Wu, 2006 (47) PreGen-Plus 52, 94 53 gFOBT, FSIG, COL 9,300–11,900 Dominated by all tests
Zauber (MISCAN), 2007 (52) PreGen-Plus 70, 96 375 gFOBT, SENSA,
COL, FSIG,
FIT, FSIG þ gFOBT
12,200–23,900 Dominated by all tests
Zauber (SimCRC), 2007 (52) PreGen-Plus 70, 96 375 gFOBT, SENSA,
COL, FSIG,
FIT, FSIG þ gFOBT
10,800–31,800 Dominated by all tests
CTC Follow-up Interval Sensitivity for
Cancer, Speciﬁcity Test Costs
b
Hassan, 2007 (44) 10 years,
all ﬁndings
95, 86 97 FSIG, COL CS Dominant vs.
FSIG, ICER
COL vs. CTC: 14,600
Ladabaum, 2004 (53) 10 years,
all ﬁndings
95, 85 1,037 COL 36,300 Dominated by COL
Pickhardt, 2007 (19) 10 years,
ﬁndings 6þ mm
95, 86 555 FSIG, COL 5,100 Dominant vs.
FSIG, ICER
COL vs. CTC: 74,200
Sonnenberg, 2000 (54) 10 years,
all ﬁndings
80, 95 741 COL 17,800 Dominated by COL
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0dominated by a guaiac-based FOBT, namely, Hemoccult
SENSA (Beckman Coulter). This comparator strategy was
not included in the former analyses, showing the dominancy
of FIT. This ﬁnding seems to indicate that FIT screening is
not cost-effective compared with Hemoccult SENSA. How-
ever, the dominancy of Hemoccult SENSA is based on US
cost estimates for FIT and guaiac FOBT, where the rates of
reimbursement for guaiac FOBTare very low at $4.50 com-
pared with $22 for FIT. In other parts of the world, the unit
costsof guaiacFOBTandFITare closer(32,33,50).A more
detailed cost-effectiveness analysis of FIT by one of the
models that found FIT to be dominated shows that, at a cost
of $17.25 per test, FIT would be a cost-effective alternative
to Hemoccult SENSA (at a per-test cost of $4.50) (51).
StoolDNAtesting wasevaluated in 5 analyses (Table 4) (39,
47, 49, 52). All studies evaluated the PreGen-Plus (EXACT
Sciences Corporation, Madison, Wisconsin), although the
different sensitivities and speciﬁcities between the studies
indicate that different versions of the test have been eval-
uated. The costs per LYG compared with no screening var-
ied from $600 to almost $32,000. All 5 models concluded
that, with performance characteristics and test costs as of
2009, stool DNA testing is dominated by the established
screening options and is therefore not cost-effective.
CTC was evaluated in 8 models (19, 22, 23, 44, 53, 54).
Half evaluated 5-yearly CTC and the other half 10-yearly
CTC. In 4 studies, a follow-up colonoscopy was assumed to
be performed for individuals with any ﬁnding at CTC; in
the other 4 studies, a follow-up colonoscopy was assumed to
be performed for only those individuals with ﬁndings 6 mm
or larger at CTC. CTC was deemed cost-effective compared
with no screening, with costs per LYG varying from cost-
saving to $36,300. However, CTC was not found to be cost-
effective in 5 of the analyses because it was dominated by
the established screening strategies. At a willingness-to-pay
threshold of $50,000 per LYG, CTC would be the recom-
mended strategy in only one of the analyses (19).
To date, the cost-effectiveness of capsule endoscopy has
been evaluated in only one known study (55). This study
showed that 10-yearly screening with capsule endoscopy
costs $31,300 per LYG compared with no screening. How-
ever, 10-yearly screening with colonoscopy was both more
effective and less costly than capsule endoscopy, and cap-
sule endoscopy was therefore dominated. Only if capsule
endoscopy was able to increase screening participation by
30% would capsule endoscopy be a cost-effective alterna-
tive for colorectal cancer screening.
DISCUSSION
This review conﬁrms the ﬁndings of the earlier USPSTF
review (4)—that colorectalcancer screeningiscost-effective
compared with no screening, irrespective of the screening
modality used. Moreover, it shows that there is a tendency
toward more favorable costs per LYG with colorectal cancer
screening in more recent years. However, as in the previous
review, no single strategy is consistently found to be the
most effective or to be preferred for a given willingness to
pay per LYG.
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Am J Epidemiol 2011;33:88–100Web Table 2 indicates several reasons for the disparate
ﬁndings between studies. Despite recommendations from
the Panel on Cost-Effectiveness in Health and Medicine
(56),this table shows that included studies still differ widely
with respect to perspective, population, time horizon, and
discount rate. These differences potentially explain the
differences in model results. However, even 2 models eval-
uating the same strategy of annual FOBT, both from a third-
party-payer perspective, looking at a cohort aged 50 years
followed for a lifetime, discounting costs and results at 3%,
arrived at very different results (37, 41).
A closer look at these studies (Web Table 2 Continued)
reveals that the costs for FOBT are 2–3 times higher in
the ﬁrst study than in the second, while FOBT sensitivity
is 60% and 40%, respectively. These differences alone may
explain a large portion of the observed differences, and we
have not yet considered differences in modeling of the
natural history of disease. Comparing the natural history
assumptions between the models proves difﬁcult. The
Sonnenberg et al. study reports an adenoma incidence of
1% per year but does not report on progression parameters
from adenoma to cancer or on progression from early to
late cancer. The models differ with respect to how the
effectiveness of screening is modeled: in the Sonnenberg
et al. model, beneﬁt of screening is an explicit model pa-
rameter of 18% for early detection and 75% for adenoma
removal; in the Khandker et al. model, the screening beneﬁt
is the result of the improved stage distribution with screen-
ing and prevention of colorectal cancer with removal of
adenomas. Thus, even when considering just 2 models, it
proves impossible to determine exactly which model param-
eters are responsible for the disparity in model outcomes.
For more models, it would become only more difﬁcult.
The model differences in adenoma dwell time and unit
test costs are most striking. The former difference seems
to occur from disparities in modeling philosophy between
studies, where short adenoma dwell times are based on as-
sumption or expert opinion and long adenoma dwell times
were calibrated to observed adenoma prevalence and polyp
growth rates. Although the calibrated dwell times have
a more empirical basis, these estimates often do not allow
for heterogeneity in adenoma dwell times, implying a very
long adenoma duration for all adenomas. The fact that there
was only very little attenuation of the protective effect
of sigmoidoscopy screening even 12 years after having the
test (57) indicates that an adenoma dwell time of 12 years
or less is unlikely and that adenoma dwell times are indeed
long for most adenomas.
In an attempt to reconcile differences between models
and determine what causes model differences, the Institute
of Medicine (58) and the National Cancer Institute’s Cancer
Intervention and Surveillance Modeling Network (59) have
offered platforms for modelers to cooperate with each other
and standardize selective model inputs such as costs and
test characteristics of their models. These exercises showed
that with standardization of these model inputs, the model
outcomes become more similar. Although the models con-
tinue to differ on the absolute costs and beneﬁts of colorectal
screening, the relative costs and effects of one screening
strategy compared with another become similar (58, 60).
Although no more than 2 of 5 models could agree on the
preferred colorectal cancer screening strategy at a willing-
ness-to-pay threshold of $50,000 with original model as-
sumptions in the Institute of Medicine workshop, all 5
models recommended the same screening strategy with
standardized model assumptions (58). However, these stan-
dardized assumptions were not evidence based, so no con-
clusions concerning the optimal colorectal cancer screening
strategy can be reached based on these results.
A joint analysis of CTC screening by the 3 colorectal
cancer models in the Cancer Intervention and Surveillance
Modeling Network group found disparate estimates for
costs per LYGs of all screening strategies. However, all 3
models were consistent in their estimated costs per LYG
of CTC screening relative to the other tests (22). In addition,
the models reached similar conclusions concerning what
level of test costs would make CTC screening cost-effective.
The fact that different models reach similar conclusions
when model inputs are standardized indicates uncertainty
regarding what the values of these inputs should be. The
differences between models (or model inputs, such as costs)
may very well reﬂect the fact that they were developed for
different settings, for example, different countries or payer
settings. If cost-effectiveness studies publish sufﬁcient
model outcomes, local decision makers should be able to
judge at least the face value of the models and translate the
outcomes to their own speciﬁc setting in which they operate.
An example of such an outcomes table has recently been
suggested (61). Cost-effectiveness of a colorectal cancer
screening test is only one of the factors inﬂuencing the de-
cision to implement a colorectal cancer screening program.
An outcomes table would provide decision makers with ad-
ditionalfactorssuchasthenumberofcolonoscopiesrequired
and the number of harms, such as the number of false-
positive test results and overdiagnosed cases (i.e., detection
of cases that would not have been detected without screen-
ing). Furthermore, with sufﬁcient details, policy makers
could apply local costs to the model outputs on tests and
colorectal cancer diagnoses and estimate cost-effectiveness
of colorectal cancer screening in their particular setting.
However, since no single colorectal cancer screening strat-
egy emerges as the most cost-effective, it is likely that
the cost-effectiveness of all established colorectal cancer
screening strategies is comparable and that other factors
such as patient acceptability, screening compliance, capital
versus operational costing, and colonoscopy and human
resources required will determine the ﬁnal verdict with
respect to which colorectal cancer screening program to
implement.
Differences in local preferences for colorectal cancer
screening are already reﬂected in the different colorectal
cancer screening policies in place throughout the world. In
Australia and Japan, colorectal cancer screening programs
are based on FIT testing. The European Union recommends
only guaiac FOBT screening and none of the other tests
because the effectiveness of these tests was not yet estab-
lished by randomized controlled trials at the time of recom-
mendation. Despite this recommendation, the colorectal
cancer screening strategies currently being implemented
in Europe differ widely between countries. Of 17 countries
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FOBT, 6 use both FOBT and endoscopy, and only 1 uses
colonoscopy (9). In the United States, all established screen-
ing strategies, and in some guidelines even the newly
developed screening strategies of stool DNA and CTC, are
recommended for the general population (5, 6). The FOBT
and endoscopic tests are currently reimbursed by Medicare
and most other health care insurers (62), so US individuals
can choose their preferred screening strategy.
Availability of (high-quality) resources for colonoscopy
and population preferences are expected to be the most
important determinants of the ﬁnal decision on which co-
lorectal cancer screening program to implement. Even with-
out a (colonoscopy) screening program, several countries
already have a waiting list for colonoscopy, with waiting
times of more than 6 months reported (63–65). Implement-
ing a guaiac FOBT screening pilot has been shown to in-
crease colonoscopy activity by 21%–31% (66). Screening
programs with FITor colonoscopy will only further increase
the demand for colonoscopy. However, even when sufﬁcient
colonoscopy capacity is available, some countries may
still opt out of implementing an invasive colonoscopy
screening program, despite colonoscopy being the most
accurate test. Some countries might prefer to offer a 2-step
approach, with a less accurate, but also less invasive strat-
egy—for example, FOBT—to stratify the population before
offering invasive colonoscopies to only those at higher risk
(i.e., with a positive result on the noninvasive test). Popu-
lation preferences are important to consider when offering
screening because, in the end, any screening test can be
effective and thus cost-effective only if the population
adheres to it.
The modeling of population adherence is an important
limitation of all of the included cost-effectiveness analyses.
Thirty of 32 models assumed the same adherence for all
screening tests. The 2 cost-effectiveness analyses that
looked at differential adherence among screening tests both
assumedahigheradherenceforFOBTcomparedwithendos-
copy (40, 47). This assumptionis supported by recent results
from a randomized controlled trial in the Netherlands that
showed a 61.5% initial uptake with FIT, a 49.5% uptake
with guaiac FOBT, and only a 32.4% uptake with sigmoid-
oscopy (67). However, these results are for initial adherence
only. FOBT is generally repeated every other year, whereas
the recommended interval for endoscopy screening is 5–10
years. To be effective, high adherence with repeat FOBT is
necessary. Experience with mammography screening has
shown that, with frequent testing, adherence may decline
over time (68). It is possible that a similar pattern may occur
for FOBT.
Even in a country such as the United States, where in-
dividuals can generally choose the colorectal cancer screen-
ing test they prefer, adherence to colorectal cancer screening
is far from perfect, with an estimated 50% of the population
having had an FOBTwithin the past year and/or endoscopy
within the past 10 years (69). This lack of adherence is one
of the reasons that new tests such as FIT, stool DNA, CTC,
and capsule endoscopy are being developed.
The included studies clearly show that, from a cost-
effectiveness point of view, only FIT may currently be ready
for widespread implementation in the general population.
There are many caveats regarding this conclusion. First,
there is no such thing as a FIT test. Instead, several FITs
are currently available, each with its own performance
characteristics and costs (70). Cost-effectiveness analyses
generally evaluate just one of the available FITs or a hypo-
thetical FIT, with test characteristics that average those
available in the literature. In this review, we simply paired
the studies evaluating FIT together without considering
which FIT was evaluated. Similar problems occur with
stool DNA testing, with several versions of the test being
available and new ones being developed (71–73).
CTC performance characteristics will highly depend
on the scan used as well as the expertise of the radiologist.
However, even when considering the same machine and
radiologist, several other aspects drastically inﬂuence the
cost-effectiveness of CTC, such as the criterion for referral
for a follow-up colonoscopy, the screening interval, and
the cost setting (e.g., public vs. private insurer). Again,
it was beyond the scope of this review to extensively exam-
ine the details concerning these settings between studies,
but these factors will inﬂuence the study results consider-
ably. Reassuringly, irrespective of the referral threshold
or screening interval considered, CTC was shown not to
be cost-effective compared with colonoscopy in the major-
ity of studies.
Despite not being cost-effective compared with the estab-
lished tests, a situation exists where implementation of
the newly developed colorectal cancer screening tests can
still be considered. If the tests would entice a previously
unscreened segment of the population to adhere to screen-
ing, the no-screening strategy would be the relevant com-
parator for these people. Since the costs per LYG of these
new tests are favorable compared with no screening,the new
tests could, in that case, be recommended. Although there
is some evidence that patients prefer CTC or stool DNA
testing over the established screening strategies, no evidence
currently shows that any of the newly developed tests in-
crease colorectal cancer screening uptake among subjects
unwilling to perform any of the established tests.
In conclusion, this review shows that colorectal cancer
screening is cost-effective compared with no screening,
but no screening method can be identiﬁed as the most effec-
tive or is the preferred strategy for a given willingness to pay
per LYG.Thisﬁnding indicates that the cost-effectivenessof
the established colorectal cancer screening tests is likely to
be comparable and that factors other than cost-effectiveness,
such as population preferences and colonoscopy resources,
might be more important in the decision about which co-
lorectal cancer screening program to introduce. The newly
developed screening tests of stool DNA testing, CTC, and
capsule endoscopy are not yet cost-effective compared with
the established screening options.
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